

# NVP-LCQ195

**Catalog No: tcsc0840**



## Available Sizes

**Size:** 5mg

**Size:** 10mg



## Specifications

**CAS No:**

902156-99-4

**Formula:**

$C_{17}H_{19}Cl_2N_5O_4S$

**Pathway:**

Cell Cycle/DNA Damage

**Target:**

CDK

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Alternative Names:**

LCQ-195;AT9311

**Observed Molecular Weight:**

460.33

## Product Description


NVP-LCQ195 (AT9311; LCQ195) is a small molecule heterocyclic inhibitor of CDK1, CDK2, CDK3 and CDK5 with IC50 of 1-42 nM.

IC50 Value: 1 nM(CDK5/p25 and CDK5/p35); 2 nM(CDK1/cyclinB and CDK2/cyclinA); 5 nM(CDK2/cyclinE); 42 nM(CDK3/cyclinE)

Target: CDKs

LCQ195 induced cell cycle arrest and eventual apoptotic cell death of MM cells, even at sub-1mol/l concentrations, spared non-malignant cells, and overcame the protection conferred to MM cells by stroma or cytokines of the bone marrow milieu. In MM cells, LCQ195 triggered decreased amplitude of transcriptional signatures associated with oncogenesis, drug resistance and stem cell renewal, including signatures of activation of key transcription factors for MM cells e.g. myc, HIF-1a, IRF4. Bortezomib-treated MM patients whose tumours had high baseline expression of genes suppressed by

LCQ195 had significantly shorter progression-free and overall survival than those with low levels of these transcripts in their MM cells. These observations provide insight into the biological relevance of multi-targeted CDK inhibition in MM.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!